SciELO - Scientific Electronic Library Online

 
vol.21 issue2Pelvic anteversion as cause of back pain, patellofemoral syndrome and growing painsHearing loss in a patient after administration of intrathecal morphine author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista de la Sociedad Española del Dolor

Print version ISSN 1134-8046

Abstract

AVELLANAL, M.; DIAZ-REGANON, G.; ORTS, A.  and  SOTO, S.. Tapentadol vs. pregabalin associated with other opioids in chronic pain management: cost-effectiveness analysis. Rev. Soc. Esp. Dolor [online]. 2014, vol.21, n.2, pp.84-88. ISSN 1134-8046.  https://dx.doi.org/10.4321/S1134-80462014000200004.

Background: Tapentadol is a new oral analgesic with a dual mode of action as a mu-opioid receptor agonist and as norepinephrine reuptake inhibitor. The cost of treatment can be argued as a problem for prescribing it. Objective: The aim of this study was to compare the cost-effectiveness of tapentadol to that of associations of other opioids with pregabalin. Patients and methods: 21 patients suffering chronic pain under treatment with opioids and pregabalin for more than 3 months and pain poorly controlled (VAS > 4) were proposed to change to tapentadol in a progressive manner: First changing the opioid to tapentadol and then removing pregabalin. Pain (VAS), daily cost of treatments and adverse effects incidence were registered. Results: Four patients returned to prior treatment because of higher incidence of adverse effects. In the group of 17 patients who completed the change of treatment pain improved from 5.7 (VAS) to 3.4 (VAS) (p < 0.001), and the cost of treatment from 4.57 €/day to 3.78 €/day (p < 0.05). Conclusion: Tapentadol treatment may be cost-effective when compared with associations of other opioids and pregabalin in patients suffering moderate to severe chronic pain. More extensive studies must be done in this sense.

Keywords : Chronic pain; Tapentadol; Pregabalin; Opioids; Cost-effectiveness.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License